Breaking News

CoreRx to Acquire Societal CDMO in $130M Deal

Will create an enhanced CDMO with broad capabilities spanning early-stage formulation development through commercial manufacturing and packaging.

Author Image

By: Charlie Sternberg

Associate Editor

CoreRx Inc. has agreed to acquire Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, in a deal valued at approximately $130 million.    Societal CDMO’s board of directors unanimously approved the transaction and plans to recommend that all shareholders tender their shares in the tender offer.   This news comes months after Societal CDMO ann...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters